SIRT4 is the molecular switch mediating cellular proliferation in colorectal cancer through GLS mediated activation of AKT/GSK3β/CyclinD1 pathway.


Journal

Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055

Informations de publication

Date de publication:
17 04 2021
Historique:
received: 30 07 2020
revised: 30 11 2020
accepted: 09 12 2020
pubmed: 15 12 2020
medline: 25 6 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

Mitochondria-localized sirtuin 4 (SIRT4) is associated with malignant phenotypes in colorectal cancer (CRC). However, the molecular mechanisms that drive SIRT4-mediated carcinogenesis are unclear. Initially, we confirmed expression of SIRT4 in CRC through public database and in CRC patient tissues using quantitative real-time reverse transcription PCR. We established HCT116 colorectal cells that overexpressed SIRT4 and HT29 cells were transfected with plasmids bearing a small interfering RNA construct to silence SIRT4. Assays to determine the malignant phenotypes (proliferation, invasion and migration) were performed. Xenograft in vivo models were also constructed. A protein interactome network was built using differentially expressed proteins identified using the liquid chromatography/tandem mass spectrophotometry, the findings of which were confirmed using co-immunoprecipitation, western blotting and phenotype rescue experiments. Decreased SIRT4 expression was associated with malignant phenotypes in vitro and in vivo. The ribosomal biogenesis pathway was enriched in the interactome network. SIRT4 suppression activated glutaminase, thereby initiating AKT activation. Our research provided novel insights into the molecular mechanisms underlying CRC, and identified that SIRT4 exerts its antitumor activity in CRC possibly dependent on glutaminase to inhibit proliferation, migration and invasion via the AKT/GSK3β/CyclinD1 pathway.

Identifiants

pubmed: 33315089
pii: 6033726
doi: 10.1093/carcin/bgaa134
doi:

Substances chimiques

CCND1 protein, human 0
Mitochondrial Proteins 0
Tumor Suppressor Proteins 0
Cyclin D1 136601-57-5
AKT1 protein, human EC 2.7.11.1
GSK3B protein, human EC 2.7.11.1
Glycogen Synthase Kinase 3 beta EC 2.7.11.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1
SIRT4 protein, human EC 3.5.1.-
Sirtuins EC 3.5.1.-
GLS protein, human EC 3.5.1.2
Glutaminase EC 3.5.1.2

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

481-492

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Ying Cui (Y)

Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.

Yibing Bai (Y)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Jiani Yang (J)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Yuanfei Yao (Y)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Chunhui Zhang (C)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Chao Liu (C)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Jiaqi Shi (J)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

QingWei Li (Q)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Jingchun Zhang (J)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Xiaolin Lu (X)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Orthopedics, Harbin Medical University Cancer Hospital, Harbin, China.

Yanqiao Zhang (Y)

Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH